SC
TARA icon

Steven Cohen’s Protara Therapeutics TARA Stock Holding History

Steven Cohen’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1M Sell
548,932
-603,782
-52% -$2.87M ﹤0.01% 2357
2026
Q1 		$6.01M Buy
1,152,714
+1,124,607
+4,001% +$6.66M 0.01% 1579
2025
Q4 		$150K Buy
+28,107
New +$156K ﹤0.01% 3690

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Steven Cohen's TARA Position: Q2 2026 in Review

Steven Cohen reduced its Protara Therapeutics (TARA) stake by 52% in Q2 2026, selling an estimated $2.87M and leaving 548,932 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2357.

Steven Cohen first reported a position in TARA in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.01M in Q1 2026. 118 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Steven Cohen held 548,932 shares of Protara Therapeutics worth $2.1M as of Q2 2026.
  • Steven Cohen sold 603,782 Protara Therapeutics shares in Q2 2026, an estimated $2.87M.
  • Protara Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #2357 holding.
  • Steven Cohen first reported a position in Protara Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Steven Cohen's Protara Therapeutics position peaked at $6.01M in Q1 2026.
  • 118 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.